Evidence map›Paper›PMID 42771308›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2027

An Overview of Programmable Epigenetic Editing Based on CRISPR Tools for Gene Expression Regulation.

Marija Djordjevič, Svetlana Dinič, Ana Sarič, Aleksandra Uskokovič, Melita Vidakovič

Abstract readReview
PubMed Publisher
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marija DjordjevičDepartment of Molecular Biology, Institute for Biological Research - National Institute of the Republic of Serbia University of Belgrade, Belgrade, Serbia.
Svetlana DiničDepartment of Molecular Biology, Institute for Biological Research - National Institute of the Republic of Serbia University of Belgrade, Belgrade, Serbia.
Ana SaričDepartment of Molecular Biology, Institute for Biological Research - National Institute of the Republic of Serbia University of Belgrade, Belgrade, Serbia.
Aleksandra UskokovičDepartment of Molecular Biology, Institute for Biological Research - National Institute of the Republic of Serbia University of Belgrade, Belgrade, Serbia.
Melita VidakovičDepartment of Molecular Biology, Institute for Biological Research - National Institute of the Republic of Serbia University of Belgrade, Belgrade, Serbia. melita@ibiss.bg.ac.rs.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic regulation provides a dynamic and reversible layer of gene control that functions independently of changes in DNA sequence, primarily mediated by DNA methylation, histone modifications, and higher-order chromatin organization. Aberrant epigenetic states contribute to a wide range of human diseases. However, conventional epigenetic therapies based on small-molecule inhibitors lack locus specificity and often cause global chromatin disturbances. The emergence of programmable epigenetic editing technologies has transformed the field by enabling targeted rewriting of chromatin states at defined genomic loci. Catalytically inactive CRISPR/Cas9 platforms fused to transcriptional activators, repressors, or chromatin-modifying enzymes now allow precise addition or removal of epigenetic marks without altering the underlying DNA sequence. This chapter provides an overview of the conceptual and technical foundations of CRISPR-based epigenetic editing, including tools for gene activation and repression, DNA methylation, histone modifications, and multiplexed systems that permit coordinated regulation of multiple genomic loci or epigenetic marks. Delivery methods for in vitro and in vivo applications are discussed, with an emphasis on viral and nonviral platforms that enable tissue-specific, durable gene regulation. Finally, recent preclinical and clinical studies highlight the potential of programmable epigenetic editing as a next-generation therapy for precise and reversible gene control.

Indexed as

CRISPR-Cas SystemsEpigenesis, GeneticEpigenome EditingGene EditingGene Expression RegulationAnimalsDNA MethylationHumansCRISPR/dCas9 toolsEpigenetic editingEpigenetic modificationsGene regulationNext-generation gene therapies

Identifiers

PMID42771308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.